Climate Change Data

Environmental Metrics

ESG Focus Areas

• Environmental Performance
• Social Responsibility
• Governance
• Health and Safety
• Business Ethics
• Human Rights
• Supply Chain Responsibility

Environmental Achievements

• Decrease in relative GHG emissions from energy consumption in the industrial plants by 16% (vs. 2017)
• Reduction of total waste generated by industrial plants by 23% in absolute terms and 21% in relative terms compared to 2017
• Improved iodine recovery at the Lanester plant

Social Achievements

• Decrease in accident frequency rate by 50% (vs. 2017)
• Launched a global referral recruitment program
• Implemented a solidarity plan with donation of days off for employees affected by reduced compensation

Governance Achievements

• Adopted the Afep-Medef Corporate Governance Code
• Established an independent alert line for ethical concerns
• Revised the Group’s Ethics Charter

Climate Goals & Targets

Environmental Challenges

• COVID-19 pandemic impacting market demand and operations
• Supply chain disruptions
• Growth of generic versions of Dotarem®
• Regulatory changes in medical devices

Mitigation Strategies

• Implemented a crisis management plan
• Optimized industrial organization and cost control
• Developed alternative sourcing strategies
• Implemented measures to ensure compliance with new regulations

Supply Chain Management

Supplier Audits: Annual assessments using the "Pestel" method, HSE evaluation table incorporated into quality audits

Responsible Procurement

• Ethical Purchasing Charter
• Supplier Code of Ethics

Climate-Related Risks & Opportunities

Physical Risks

• Extreme weather phenomena

Transition Risks

• Regulatory changes (carbon tax, energy efficiency)
• Resource scarcity

Opportunities

• Increased customer demand for sustainable products
• Innovation in energy-efficient technologies

Sustainable Products & Innovation

• ScanBag® by Xenetix®

Environmental Metrics

ESG Focus Areas

• Employee safety
• Environment
• Ethics

Social Achievements

• Ranked 147th overall and 12th in the Healthcare and Pharmaceutical business sector in Le Point's 2022 list of most responsible companies in France.
• Awarded an A rating in the Helpévia sustainable development questionnaire.

Governance Achievements

• Obtained a B rating from CDP in the Climate Questionnaire for the third consecutive year.

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Awards & Recognition

• Ranked 10th in the national rankings of the Gaïa-Index.
• Ranked 147th overall and 12th in the Healthcare and Pharmaceutical business sector in Le Point's 2022 list of most responsible companies in France.

Environmental Metrics

ESG Focus Areas

• Climate Change
• Human Resources
• Health and Safety
• Environmental Impact
• Business Ethics
• Responsible Use of Laboratory Animals

Environmental Achievements

• US FDA marketing authorization for Elucirem™, an MRI innovation requiring half the gadolinium dose compared to existing products, reducing environmental footprint.
• Adoption of a Climate Strategy with emission reduction targets for direct and indirect emissions by 2032, aligned with a "Well below 2°C" trajectory.

Social Achievements

• Successful industrialization of Elucirem™ in French and US plants.
• Workforce stabilization by the end of 2022 despite high employee turnover in the US.
• Acquisition of a 39% stake in Intrasense, a medical imaging software company specializing in AI, strengthening AI ambitions.

Governance Achievements

• Separation of Chairperson of the Board of Directors and Chief Executive Officer functions.
• Adoption of the Afep-Medef Corporate Governance Code (with some deviations noted).

Climate Goals & Targets

Environmental Challenges

• Supply chain disruptions due to global events (COVID-19, inflation, conflicts).
• High employee turnover, especially in the US.
• Rising energy costs.
• Production delays at the Raleigh plant affecting Optiray® and pre-filled syringes.

Mitigation Strategies

• Production largely located in Europe and the US to limit supply risks.
• Workforce stabilization measures implemented.
• Existing purchasing policies and contracts absorbed rising energy costs.
• Addressing Raleigh plant production delays through prioritization of Elucirem™ production and increased hiring.

Supply Chain Management

Supplier Audits: Several times a year using the "Pestel" method for strategic suppliers.

Responsible Procurement

• Supplier Code of Ethics
• Medium- and long-term supply agreements
• Second source qualification for strategic raw materials.

Climate-Related Risks & Opportunities

Physical Risks

• Severe and chronic weather phenomena (temperature, drought, precipitation, natural disasters)

Transition Risks

• Resource scarcity
• Stringent regulations
• Reputational issues

Opportunities

• Energy efficiency improvements
• Renewable energy adoption

Reporting Standards

Frameworks Used: SBTi

Certifications: ISO 14001 (Dublin plant)

Third-party Assurance: Independent third-party verification of non-financial performance statement

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Elucirem™ (reduced gadolinium dose)
• Xenetix® eco-designed packaging (Scanbag®)

Awards & Recognition

• 2021 Loire-Brittany water award (Lanester plant)
• 2021 LEEM CSR award (Lanester plant)

Environmental Metrics

ESG Focus Areas

• People
• Planet
• Business Ethics

Environmental Achievements

• Reduced scopes 1 & 2 emissions by 27.5% between 2021 and 2032
• Reduced scope 3 emissions by 3.5% between 2021 and 2032
• Recycles 4,500 metric tons of solvents in Dublin and more than 200 metric tons of iodine in Lanester annually.
• Opened a solar farm at its Dublin plant in December 2023.

Social Achievements

• Launched Elucirem™, reducing patients' gadolinium exposure by half.
• Acquired a majority stake in Intrasense to become a major player in AI for medical imaging.
• Doubled sales in China since 2021 (at constant exchange rates).
• Doubled sales in Japan in three years following the “Go-Direct” initiative.

Governance Achievements

• Adopted the Afep-Medef Corporate Governance Code.
• Separated the functions of Chairperson of the Board and CEO.
• Implemented a robust risk management system aligned with the three lines of control.

Climate Goals & Targets

Environmental Challenges

• Inflation on raw materials (iodine), components, and packaging.
• Supply chain disruptions due to geopolitical tensions and raw material scarcity.
• Cybersecurity risks and information system failures.
• Climate change related physical and transition risks.

Mitigation Strategies

• Cost control policies and negotiations with suppliers.
• Alternative sourcing strategies and inventory adjustments.
• Enhanced cybersecurity measures, including training and system upgrades.
• Climate risk assessment, decarbonization roadmap, and energy efficiency measures.

Supply Chain Management

Responsible Procurement

• Ethical Purchasing Charter
• Supplier Code of Ethics
• CSR criteria in supplier selection

Climate-Related Risks & Opportunities

Physical Risks

• Severe weather events impacting industrial plants and suppliers

Transition Risks

• Resource scarcity
• Regulatory changes
• Reputational risks

Opportunities

• Development of energy-efficient products and processes

Reporting Standards

Frameworks Used: Afep-Medef Code, CSRD, SBTi

Certifications: ISO 14001 (Dublin plant)

Third-party Assurance: Independent third-party organization

UN Sustainable Development Goals

• Goal 3 (Good Health and Well-being)
• Goal 9 (Industry, Innovation, and Infrastructure)
• Goal 12 (Responsible Consumption and Production)
• Goal 13 (Climate Action)

Guerbet's activities contribute to these goals through its contrast media, medical devices, and sustainable development initiatives.

Sustainable Products & Innovation

• Elucirem™ (reduced gadolinium dose)
• ScanBag® by Xenetix® (eco-designed packaging)

Awards & Recognition

• Gaïa Index gold level
• CDP climate & water level B
• Statista ranking (120th out of 250 companies, 9th in health and pharmaceutical category)